Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).

被引：4
|
作者：
Quintela-Fandino, Miguel
Apala, Juan V.
Salgado, Alfonso Cortes
Mouron, Silvana Andrea
Guerra, Juan Antonio
Cortes, Mana Gion
Morente, Manuel
Manso, Luis
机构：
[1] CNIO Spanish Natl Canc Res Ctr, Madrid, Spain
[2] CNIO, Madrid, Spain
[3] Hosp Ramon & Cajal, Madrid, Spain
[4] Spanish Natl Canc Res CNIO, Breast Canc Clin Res Unit, Madrid, Spain
[5] Hosp Fuenlabrada, Madrid, Spain
[6] Hosp 12 Octubre, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2552
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized phase 0 trial of the mitochondria! inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC).
    Quintela-Fandino, Miguel
    Morales, Serafin
    Cortes Salgado, Alfonso
    Manso, Luis
    Apala, Juan V.
    Cortes, Javier
    Antonio Guerra, Juan
    Caleiras, Eduardo
    Mulero, Francisca
    Andrea Mouron, Silvana
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Randomized Phase O/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer
    Quintela-Fandino, Miguel
    Morales, Serafin
    Cortes-Salgado, Alfonso
    Manso, Luis
    Apala, Juan V.
    Munoz, Manuel
    Gasol Cudos, Ariadna
    Salla Fortuny, Joel
    Gion, Maria
    Lopez-Alonso, Antonio
    Cortes, Javier
    Guerra, Juan
    Malon, Diego
    Caleiras, Eduardo
    Mulero, Francisca
    Mouron, Silvana
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 35 - 45
  • [3] Treatment of HER2-negative metastatic breast cancer (MBC) with bevacizumab (BEV) plus paclitaxel (TXL): A singlecenter phase II study
    Inno, A.
    Strippoli, A.
    Nazzicone, G.
    Quaranta, A.
    Di Salvatore, M.
    Galiano, A.
    Bagala, C.
    Basso, M.
    Pozzo, C.
    Cassano, A.
    Astone, A.
    Barone, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
    Gligorov, Joseph
    Bines, Jose
    Alba, Emilio
    Mustacchi, Giorgio
    Cinieri, Saverio
    Gupta, Vineet
    Pierga, Jean-Yves
    Bozcuk, Hakan
    Gaafar, Rabab
    Gupta, Sudeep
    Vivanco, Guillermo Lopez
    Wang, Xiaojia
    Costa, Romulo
    Altundag, Kadri
    Chmielowska, Ewa
    de Ducla, Sabine
    Freudensprung, Ulrich
    Cortes, Paulo
    Doval, Dinesh
    CANCER RESEARCH, 2015, 75
  • [5] Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez-Martin, A.
    Ebel, K.
    Easton, V.
    von Minckwitz, G.
    CANCER RESEARCH, 2016, 76
  • [6] Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Gligorov, Joseph
    Marschner, Norbert
    Zielinski, Christoph
    de Laurentiis, Michele
    Brain, Etienne
    Levy, Christelle
    Welt, Anja
    Kahan, Zsuzsanna
    Inbar, Moshe
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
  • [7] Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).
    Brufsky, Adam M.
    Hurvitz, Sara A.
    Perez, Edith A.
    Yamamoto, Hideharu
    Valero, Vicente
    O'Neill, Vincent
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [8] Phase II trial evaluating the combination of eribulin (E) plus bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
    Hardy-Bessard, A-C.
    Brocard, F.
    Leheurteur, M.
    Melis, A.
    Dauba, J.
    Lortholary, A.
    You, B.
    Guardiola, E.
    Grenier, J.
    Martin-Babau, J.
    Meunier, J.
    Follana, P.
    Savoye, A-M.
    Mercier-Blas, A.
    Marti, A.
    Despax, R.
    Barbier, N.
    Gane, N.
    Ardisson, P.
    Segura-Djezzar, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
    Miles, D. W.
    De Haas, S. L.
    Romieu, G.
    Chan, A.
    Dirix, L.
    Cortess, J.
    Delmar, P. R.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S176 - S176
  • [10] Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)
    Cortes, Javier
    Vrdoljak, Eduard
    Puglisi, Fabio
    Marschner, Norbert
    Gligorov, Joseph
    Zielinski, Christoph
    Villanueva, Cristian
    Romieu, Gilles
    Lang, Istvan
    Ciruelos, Eva
    Veyret, Corinne
    Fontana, Andrea
    Oestergaard, Mikkel
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
12345